HCID 4616003, Verbindung → 2-(2-Furan-2-ylmethyl-3-oxo-2,3-dihydro-1H-isoindol-1-ylsulfanyl)-N-thiazol-2-yl-acetamide
Reaktionsgleichung
[OH:1]C1C2C(=CC=CC=2)C(=O)N1CC1SC=CC=1.[O:18]=[C:19]1[C:27]2[C:22](=[CH:23][CH:24]=[CH:25][CH:26]=2)[CH:21]([S:28][CH2:29][C:30]([NH:32][C:33]2[S:34][CH:35]=[CH:36][N:37]=2)=[O:31])[N:20]1[CH2:38][C:39]1S[CH:41]=[CH:42][CH:43]=1>>[O:1]1[CH:41]=[CH:42][CH:43]=[C:39]1[CH2:38][N:20]1[C:19](=[O:18])[C:27]2[C:22](=[CH:23][CH:24]=[CH:25][CH:26]=2)[CH:21]1[S:28][CH2:29][C:30]([NH:32][C:33]1[S:34][CH:35]=[CH:36][N:37]=1)=[O:31]Komponenten
3
Versuchsvorschrift
Compound 32 was prepared using the synthetic sequence in a manner analogous to the method described for the conversion of compound 12 to compound 14 and illustrated in Scheme 1b. 1H NMR (300 MHz, DMSO): δ 11.96 (s, 1H), 7.71 (d, J=8 Hz, 1H), 7.59 (m, 4H), 7.48 (m, 2H), 7.42 (d, J=4 Hz, 1H), 7.19 (d, J=4 Hz, 1H), 5.76 (s, 1H), 4.97 (d, J=16 Hz, 1H), 4.44 (d, J=16 Hz, 1H), 3.09 (d, J=15 Hz, 1H), 2.95 (d, J=15 Hz, 1H). MS: m/z (MH+) 386.